March 26, 2018
The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma patients with the t(11;14) translocation evident on FISH (fluorescence in situ hybridization) testing of bone marrow myeloma cells. This landmark retrospective analysis assesses the 16-to-24-percent of myeloma patients harboring the t(11;14) translocation. The...
Continue Reading
Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple Myeloma (MM) is the second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, yet few people know much about this deadly disease. The American Cancer Society’s estimates for multiple myeloma in the United States for...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand